1. Home
  2. LSBK vs IPHA Comparison

LSBK vs IPHA Comparison

Compare LSBK & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LSBK

Lake Shore Bancorp Inc.

HOLD

Current Price

$15.95

Market Cap

125.6M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.40

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSBK
IPHA
Founded
1891
1999
Country
United States
France
Employees
N/A
163
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
131.4M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
LSBK
IPHA
Price
$15.95
$1.40
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
4.4K
23.2K
Earning Date
04-22-2026
03-26-2026
Dividend Yield
2.27%
N/A
EPS Growth
49.23
N/A
EPS
0.97
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$16.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.50
$1.18
52 Week High
$16.28
$2.63

Technical Indicators

Market Signals
Indicator
LSBK
IPHA
Relative Strength Index (RSI) 57.90 50.44
Support Level $14.57 $1.35
Resistance Level $16.28 $1.80
Average True Range (ATR) 0.12 0.08
MACD -0.02 -0.00
Stochastic Oscillator 33.36 50.00

Price Performance

Historical Comparison
LSBK
IPHA

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: